Testosterone Cypionate Pediatric Transition to Adult Care

Why Testosterone Cypionate Is Used Before Age 12

Testosterone cypionate appears in pediatric practice for a small but clinically significant group of patients. The most common indications are primary hypogonadism from chromosomal disorders, hypothalamic or pituitary failure from tumors or cranial radiation, and, less often, delayed puberty requiring short-course induction. These are not cosmetic or performance applications. They are endocrine replacement therapies for documented hormone deficiency.

Conditions That Drive Pediatric Testosterone Use

Klinefelter syndrome (47,XXY) is the most prevalent cause of primary hypogonadism in genetic males, affecting approximately 1 in 660 live male births according to data compiled by the National Institutes of Health [1]. Testosterone production from Leydig cells is progressively impaired, and some patients require replacement before age 12 when growth or metabolic complications are present.

Hypothalamic-pituitary axis damage from cranial irradiation for medulloblastoma or acute lymphoblastic leukemia can produce gonadotropin deficiency. A 2014 analysis published in the Journal of Clinical Endocrinology and Metabolism found that gonadotropin deficiency occurred in up to 20% of childhood cancer survivors who received hypothalamic-pituitary radiation doses exceeding 30 Gy [2].

Congenital hypogonadotropic hypogonadism (CHH) including Kallmann syndrome produces absent or severely blunted GnRH pulsatility. Without testosterone replacement or gonadotropin therapy, these patients will not progress through puberty spontaneously [3].

Why Cypionate Specifically

Testosterone cypionate is an esterified form of testosterone suspended in cottonseed oil, administered intramuscularly. Its half-life of approximately 8 days allows every-2-week or every-4-week dosing schedules, which suits pediatric compliance patterns better than shorter-acting formulations [4]. The FDA has approved testosterone cypionate for hypogonadism in males, though use in children under 12 is largely off-label, meaning prescribing physicians rely on Endocrine Society guidelines and published case series rather than labeled indications [5].

The Clinical Case for a Structured Transition Protocol

Pediatric patients on testosterone cypionate do not simply age into adult care. They carry diagnostic complexity, incomplete pubertal histories, bone age discrepancies, and often psychological burdens from chronic disease. A disorganized handoff produces real harm. Studies examining transition in adolescents with chronic endocrine conditions show that loss of follow-up during the handoff period is associated with a measurable decline in treatment adherence and an increase in disease-related complications [6].

What Goes Wrong Without a Protocol

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states directly: "We recommend against starting testosterone therapy in patients in whom the diagnosis of hypogonadism has not been confirmed with two morning testosterone measurements and an assessment of symptoms and signs" [7]. This recommendation exists partly because pediatric diagnoses are sometimes made under urgent or incomplete circumstances. A transition is an opportunity to re-confirm the original diagnosis under adult diagnostic criteria before committing the patient to lifelong therapy.

Bone density loss is the most immediate physiological risk when testosterone is withdrawn or interrupted during a transition gap. Testosterone drives skeletal mineralization through aromatization to estradiol. A gap of even 6 months at the wrong developmental window can reduce bone mineral density at the lumbar spine, a deficit that may not fully recover [8].

Elements of a Formal Transition Readiness Assessment

A structured readiness assessment before transfer to adult care should cover four domains:

1. Diagnostic confirmation. Two morning total testosterone levels drawn at least one week apart, with LH and FSH to differentiate primary from secondary hypogonadism. The Endocrine Society defines biochemical hypogonadism as a total testosterone consistently below 300 ng/dL in adults, but pediatric thresholds are age- and stage-specific [7].

2. Bone age and density. A DEXA scan at the lumbar spine and total hip, plus a left-hand X-ray for bone age if the patient is still growing. Bone age should be within 2 years of chronological age for the transition plan to proceed without delay.

3. Metabolic panel. Hematocrit (target <54%), lipid panel, liver function tests, and fasting glucose. Testosterone cypionate raises hematocrit through erythropoiesis stimulation, and pediatric patients who have been on therapy for years may already be near the upper boundary [9].

4. Psychosocial readiness. Ability to self-administer injections or manage a caregiver who will. Understanding of the lifelong nature of the therapy. Identification of an adult endocrinologist or primary care provider who manages hypogonadism.

Dosing at Transition: From Pediatric Schedules to Adult Targets

Pediatric dosing of testosterone cypionate is weight-based and stage-based, not the flat-dose adult approach. A typical induction protocol starts at 25 mg IM every 4 weeks and increases in 25 mg increments every 6 months, guided by clinical pubertal staging and bone age [3]. By the time a patient approaches transition, they may be on 50 to 100 mg every 2 weeks, which is still below the standard adult maintenance range.

Adult Dosing Targets

The standard adult dose of testosterone cypionate for hypogonadism is 100 to 200 mg IM every 2 weeks, targeting a mid-cycle total testosterone of 400 to 700 ng/dL [7]. Some adult providers shift patients to weekly injections of 50 to 100 mg to reduce the peak-to-trough swing, which can cause mood instability and fatigue near the end of a 2-week cycle. This is a pharmacokinetic preference, not a guideline requirement.

A pre-transition trough testosterone level (drawn immediately before the next injection) tells the adult provider whether the current dose is maintaining therapeutic levels or leaving the patient under-replaced for days at a time [4].

Dose Escalation Timeline

Moving from a pediatric dose to a full adult dose should not happen in a single visit. A reasonable schedule advances the dose by 25 to 50 mg every 8 to 12 weeks, with a hematocrit check before each escalation. The American Association of Clinical Endocrinologists recommends withholding dose increases if hematocrit exceeds 50% and suspending therapy temporarily if it exceeds 54% [10].

Laboratory Monitoring Schedule at and After Transition

Monitoring does not decrease at transition. If anything, the re-titration phase requires more frequent checks than a stable adult patient on long-term therapy.

Pre-Transfer Labs (3 to 6 Months Before Handoff)

• Total testosterone (mid-cycle and trough)
• LH, FSH
• SHBG (to calculate free testosterone if total is borderline)
• Hematocrit and hemoglobin
• Lipid panel
• Liver enzymes
• DEXA scan if not done within 2 years
• Bone age X-ray if still growing

Post-Transfer Labs (First 12 Months in Adult Care)

Labs at 3 months, then 6 months, then annually once stable. The FDA label for testosterone cypionate specifies hematocrit monitoring at baseline, 3 to 6 months after starting or changing dose, and annually thereafter [5]. This schedule applies directly to patients coming out of pediatric care on an escalating dose.

A 2019 study in the Journal of Clinical Endocrinology and Metabolism found that adolescent males with Klinefelter syndrome who maintained testosterone levels above 300 ng/dL during the transition period had significantly better bone mineral density outcomes at age 25 compared to those whose levels dropped during the handoff period (p<0.01) [11].

The Role of Fertility Preservation Before Committing to Testosterone

This point often goes unaddressed in pediatric handoffs. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH, which in turn suppresses intratesticular testosterone and spermatogenesis. This is not a reason to withhold medically necessary testosterone, but it is a reason for a documented conversation.

The American Society for Reproductive Medicine (ASRM) recommends that fertility counseling occur before initiating or continuing androgen therapy in any patient who has not completed family planning [12]. For a patient transitioning to adult care, this conversation belongs in the handoff summary. If the patient is 16 or 17, they may already have opinions about future fertility that were not solicited when the original pediatric prescription was written.

Patients with hypogonadotropic hypogonadism (Kallmann syndrome, CHH) have a meaningful chance of spermatogenesis induction with gonadotropin therapy (hCG with or without FSH) if exogenous testosterone is discontinued and replaced with pulsatile GnRH or gonadotropin injections [3]. This option should be documented and offered, not assumed to be irrelevant.

Psychological and Developmental Considerations

A child who started testosterone replacement before age 12 has never known life without it. The psychological context is different from an adult who is newly diagnosed with hypogonadism. These patients may have internalized their diagnosis differently, have varying levels of health literacy about their condition, and may feel anxiety about taking on self-management responsibility.

Building Self-Management Skills Before Transfer

Transition programs in pediatric endocrinology increasingly use structured self-management checklists. The American Academy of Pediatrics supports a "transition readiness" model in which the pediatric team progressively shifts responsibility to the adolescent patient starting at age 14, so that by the time of formal transfer, the patient is already managing most of their own care [13].

For testosterone cypionate specifically, self-management skills include:

• Drawing up the correct dose from a vial
• Identifying appropriate injection sites (gluteus medius, vastus lateralis)
• Recognizing signs of injection site reactions
• Knowing when to call a provider (polycythemia symptoms, extreme mood changes, injection site abscess)

Mental Health Screening at Transition

Hypogonadism in males is associated with elevated rates of depression and anxiety. A 2020 meta-analysis in JAMA Network Open found that men with testosterone deficiency had a significantly higher prevalence of depressive symptoms compared to eugonadal controls across 27 studies [14]. Transitioning patients deserve a mental health screening at the time of handoff, not as an afterthought but as a standard component of the clinical summary.

Structuring the Handoff Document

The pediatric provider owes the receiving adult team a complete clinical narrative. A transfer summary for a patient on testosterone cypionate should contain:

• Original diagnosis with supporting lab values and dates
• Chromosomal or genetic testing results (e.g., karyotype confirming 47,XXY)
• Full medication history including all dose changes and reasons
• Most recent labs with dates
• Current dose, injection schedule, and site preferences
• DEXA results and bone age history
• Growth chart data
• Fertility discussion documentation
• Mental health history and current status
• Patient's own understanding of their diagnosis

The Endocrine Society's Pediatric Endocrine Society joint guidance on transition of care recommends that this summary be shared with the patient, the adult provider, and a primary care physician simultaneously, so that no single point of failure can leave the patient without a prescriber [6].

Red Flags During the Transition Period

Some findings require immediate clinical attention rather than a scheduled follow-up.

Hematocrit above 54% requires dose hold and evaluation for secondary causes of erythrocytosis. Testosterone-induced polycythemia raises thrombosis risk, and the FDA label specifies this as a reason to suspend therapy [5].

Testosterone level below 200 ng/dL at mid-cycle suggests under-dosing or non-adherence, both of which need addressing before they cause symptomatic hypogonadism or bone loss.

Injection site nodules or abscesses require wound evaluation and possible technique review. Cypionate in oil vehicle can cause sterile granulomas if injected into subcutaneous fat rather than muscle.

Mood instability with a documented peak-to-trough testosterone swing exceeding 400 ng/dL may indicate the patient would do better on weekly rather than biweekly injections, or on a long-acting formulation.

What Adult Providers Need to Know Coming In

Adult endocrinologists and primary care providers managing TRT are accustomed to de novo diagnoses. A pediatric transfer is different. The patient has years of treatment history, a childhood-onset diagnosis, and possibly incomplete virilization depending on when therapy started and how consistently it was maintained.

The adult provider should not assume that the pediatric diagnosis is finalized until they have reviewed original documentation. They should repeat confirmatory testing if records are incomplete. And they should not change the dose or formulation in the first visit without a full picture of the patient's current status [7].

The first adult visit is an assessment visit, not a prescription renewal visit. This framing reduces the risk of errors and builds the foundation for a therapeutic relationship that may last decades.